🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms

Recruitingn/aAges 18 Years - anyAllAzienda Ospedaliera Brotzu
NCT07522008 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Many patients receiving maintenance hemodialysis continue to experience persistent uremic symptoms, such as pruritus, fatigue, sleep disorders, reduced physical performance, and impaired quality of life, despite optimized dialysis prescriptions. Conventional dialysis techniques mainly rely on diffusion and convection and may be insufficient to remove certain uremic toxins, particularly protein-bound and middle-molecule solutes. Purpose: The ICHARUS study (Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms) is a prospective, observational, real-world registry designed to evaluate the clinical use of hemodialysis combined with hemoadsorption (HAHD) in patients with persistent uremic symptoms. Study design: ICHARUS is a multicenter registry enrolling adult patients on maintenance hemodialysis in whom hemoadsorption is prescribed according to routine clin

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients (≥18 years) with end-stage kidney disease (CKD stage 5D) on maintenance hemodialysis. * Stable hemodialysis treatment for at least 3 months prior to enrollment. * Presence of at least one moderate-to-severe uremic symptom, as identified by the Dialysis Symptom Index at screening. * Planned treatment with hemodialysis combined with hemoadsorption according to local clinical practice. * Ability to provide written informed consent. Exclusion Criteria: * Acute illness, active infection, or hospitalization within 4 weeks prior to enrollment. * Planned kidney transplantation within the study follow-up period. * Life expectancy less than 6 months due to non-renal comorbid conditions. * Inability to complete patient-reported outcome questionnaires. * Participation in another interventional clinical study that could interfere with study outcomes.
💊

What it tests

  • Not listed
📍

Where

1 site
S.C.D.U. Nefrologia, Dialisi e Trapianto ARNAS G.Brotzu, Cagliari
Cagliari, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy